Cited by 646Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchAldose Reductase and Taurine

The DOI matches its Crossref record; 324 of the 326 references it cites were found in a registry or an index.

Tau protein kinases: Involvement in Alzheimer's disease

Martin, Ludovic, Latypova, Xenia, Wilson, Cornelia M., Magnaudeix, Amandine, Perrin, Marie-Laure, Yardin, Catherine, Terro, Faraj·2013·Ageing Research Reviews

DOI 10.1016/j.arr.2012.06.003

Open this paper in CoChat — free account

Abstract

Tau phosphorylation is regulated by a balance between tau kinase and phosphatase activities. Disruption of this equilibrium was suggested to be at the origin of abnormal tau phosphorylation and thereby might contribute to tau aggregation. Thus, understanding the regulation modes of tau phosphorylation is of high interest in determining the possible causes at the origin of the formation of tau aggregates in order to elaborate protection strategies to cope with these lesions in Alzheimer's disease. Among the possible and specific interventions that reverse tau phosphorylation is the inhibition of certain tau kinases. Here, we extensively reviewed tau protein kinases, their physiological roles and regulation, their involvement in tau phosphorylation and their relevance to AD. We also reviewed the most common inhibitory compounds acting on each tau kinase.

Integrity signals

Registry

Crossref · 10.1016/j.arr.2012.06.003

Cites

324 of 324 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo
Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27489 · Cited by 3,374
Mechanism of activation of protein kinase B by insulin and IGF‐1.
Alessi, D. R., Andjelković, M., Caudwell, B., Cron, P. D., MORRICE, N. A., Cohen, P., & Hemmings, B. A. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01045.x · Cited by 3,014
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., & Saltiel, A. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7686 · Cited by 2,679
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase
Bennett, B. L., Sasaki, D. T., Murray, B. W., O'Leary, E. C., Sakata, S. T., Xu, W., Leisten, J. C., Motiwala, A., Pierce, S., Satoh, Y., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251194298 · Cited by 2,558
The selectivity of protein kinase inhibitors: a further update
Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., McLauchlan, H., Klevernic, I. V., Arthur, J. S. C., Alessi, D. R., & Cohen, P. (2007) · Biochemical Journal · doi:10.1042/bj20070797 · Cited by 2,522
The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C.
Toullec, D., Pianetti, P., Coste, H., Bellevergue, P., Grand-Perret, T., Ajakane, M., Baudet, V., Boissin, P., Boursier, E., & Loriolle, F. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98476-0 · Cited by 2,446

Flagged first, then by citations

Show all 326 references

2 of the 326 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Alvarez, 1999, Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloid-induced neuronal death, 15, 421

Sorted by citations

Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer’s Disease
Wesseling, H., Mair, W., Kumar, M., Schlaffner, C. N., Tang, S., Beerepoot, P., Fatou, B., Guise, A. J., Cheng, L., Takeda, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.029 · Cited by 688
Three dimensions of the amyloid hypothesis: time, space and 'wingmen'
Musiek, E. S., & Holtzman, D. M. (2015) · Nature Neuroscience · doi:10.1038/nn.4018 · Cited by 662
Tau and tauopathies
Arendt, T., Stieler, J. T., & Holzer, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.08.018 · Cited by 609
Altered Insulin Signaling in Alzheimer’s Disease Brain – Special Emphasis on PI3K-Akt Pathway
Gabbouj, S., Ryhänen, S., Marttinen, M., Wittrahm, R., Takalo, M., Kemppainen, S., Martiskainen, H., Tanila, H., Haapasalo, A., Hiltunen, M., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00629 · Cited by 401
Pathological mechanisms and therapeutic strategies for Alzheimer’s disease
Tam, K. Y., & Ju, Y. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.320970 · Cited by 422
Friend or foe—Post-translational modifications as regulators of phase separation and RNP granule dynamics
Hofweber, M., & Dormann, D. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.tm118.001189 · Cited by 398
α-synuclein in the pathophysiology of Alzheimer’s disease
Twohig, D., & Nielsen, H. M. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0320-x · Cited by 374
Tau and neuroinflammation: what impact for Alzheimer's disease and tauopathies?
Laurent, C., Buée, L., & Blum, D. (2018) · Biomedical Journal · doi:10.1016/j.bj.2018.01.003 · Cited by 348
MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer’s disease
Banzhaf‐Strathmann, J., Benito, E., May, S., Arzberger, T., Tahirovic, S., Kretzschmar, H., Fischer, A., & Edbauer, D. (2014) · The EMBO Journal · doi:10.15252/embj.201387576 · Cited by 347
Comprehensive review of mechanisms of pathogenesis involved in Alzheimer’s disease and potential therapeutic strategies
Sharma, P., Srivastava, P., Seth, A., Tripathi, P. N., Banerjee, A. G., & Shrivastava, S. K. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.006 · Cited by 331
Role of tau protein in Alzheimer’s disease: The prime pathological player
Muralidar, S., Ambi, S. V., Sekaran, S., Thirumalai, D., & Palaniappan, B. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.07.327 · Cited by 278
Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents
Jouanne, M., Rault, S., & Voisin‐Chiret, A. S. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.070 · Cited by 279
Protein phosphorylation in neurodegeneration: friend or foe?
Tenreiro, S., Eckermann, K., & Outeiro, T. F. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00042 · Cited by 252
Epigenetic dysregulation of enhancers in neurons is associated with Alzheimer’s disease pathology and cognitive symptoms
Li, P., Marshall, L., Oh, G., Jakubowski, J. L., Groot, D., He, Y., Wang, T., Petronis, A., & Labrie, V. (2019) · Nature Communications · doi:10.1038/s41467-019-10101-7 · Cited by 234
Four-repeat tauopathies
Rösler, T. W., Marvian, A. T., Brendel, M., Nykänen, N.-P., Höllerhage, M., Schwarz, S. C., Hopfner, F., Koeglsperger, T., Respondek, G., Schweyer, K., et al. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101644 · Cited by 231
Nanotechnology-based drug delivery systems for Alzheimer's disease management: Technical, industrial, and clinical challenges
Wen, M. M., El-Salamouni, N. S., El-Refaie, W. M., Hazzah, H. A., Ali, M. M., Tosi, G., Farid, R. M., Blanco‐Prieto, M. J., Billa, N., & Hanafy, A. S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.025 · Cited by 228
“Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies
Xia, Y., Prokop, S., & Giasson, B. I. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00460-5 · Cited by 227
Tau Protein Interaction Partners and Their Roles in Alzheimer’s Disease and Other Tauopathies
Sinsky, J., Pichlerova, K., & Hanes, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179207 · Cited by 220
Nanotechnology-based strategies for siRNA brain delivery for disease therapy
Zheng, M., Tao, W., Zou, Y., Farokhzad, O. C., & Shi, B. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.01.006 · Cited by 210
Updates in Alzheimer's disease: from basic research to diagnosis and therapies
Liu, E., Zhang, Y., & Wang, J. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00432-x · Cited by 241
Modeling Sporadic Alzheimer's Disease in Human Brain Organoids under Serum Exposure
Chen, X., Sun, G., Tian, E., Zhang, M., Davtyan, H., Beach, T. G., Reiman, E. M., Blurton‐Jones, M., Holtzman, D. M., & Shi, Y. (2021) · Advanced Science · doi:10.1002/advs.202101462 · Cited by 200
Tau-Centric targets and drugs in clinical development for the treatment of alzheimer's disease
Panza, F., Solfrizzi, V., Seripa, D., Imbimbo, B. P., Lozupone, M., Santamato, A., Zecca, C., Barulli, M. R., Bellomo, A., Pilotto, A., et al. (2016) · BioMed Research International · doi:10.1155/2016/3245935 · Cited by 195
Flavonoids as Therapeutic Compounds Targeting Key Proteins Involved in Alzheimer’s Disease
Baptista, F. I., Henriques, A. G., Silva, A. M. S., Wiltfang, J., & Silva, O. A. B. D. C. E. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400213r · Cited by 195
Revisiting the grammar of Tau aggregation and pathology formation: how new insights from brain pathology are shaping how we study and target Tauopathies
Limorenko, G., & Lashuel, H. A. (2021) · Chemical Society Reviews · doi:10.1039/d1cs00127b · Cited by 168
Early etiology of Alzheimer’s disease: tipping the balance toward autophagy or endosomal dysfunction?
Peric, A., & Annaert, W. G. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1379-7 · Cited by 172
GSK3β and tau protein in Alzheimer's disease and epilepsy
Toral-Rios, D., Pichardo-Rojas, P. S., Alonso-Vanegas, M., & Campos-Peña, V. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00019 · Cited by 158
Alzheimer's disease, enzyme targets and drug discovery struggles: From natural products to drug prototypes
Silva, T., Reis, J., Teixeira, J., & Borges, F. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.03.008 · Cited by 158
Mechanism involved in insulin resistance via accumulation of β-amyloid and neurofibrillary tangles: link between type 2 diabetes and Alzheimer’s disease
Rad, S. K., Arya, A., Karimian, H., Madhavan, P., Rizwan, F., Koshy, S., & Prabhu, G. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s173970 · Cited by 167
FLEXITau: Quantifying Post-translational Modifications of Tau Protein in Vitro and in Human Disease
Mair, W., Muntel, J., Tepper, K., Tang, S., Biernat, J., Seeley, W. W., Kosik, K. S., Mandelkow�, E., Steen, H., & Steen, J. A. J. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.5b04509 · Cited by 144
Retinal changes in Alzheimer's disease— integrated prospects of imaging, functional and molecular advances
Gupta, V. B., Chitranshi, N., den Haan, J., Mirzaei, M., You, Y., Lim, J. K. H., Basavarajappa, D. K., Godinez, A., Angelantonio, S. D., Sachdev, P. S., et al. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100899 · Cited by 149
Linking Traumatic Brain Injury to Chronic Traumatic Encephalopathy: Identification of Potential Mechanisms Leading to Neurofibrillary Tangle Development
Lucke-Wold, B. P., Turner, R. C., Logsdon, A. F., Bailes, J. E., Huber, J. D., & Rosen, C. L. (2014) · Journal of Neurotrauma · doi:10.1089/neu.2013.3303 · Cited by 145
Polymeric Nanoparticles for Nasal Drug Delivery to the Brain: Relevance to Alzheimer's Disease
Rabiee, N., Ahmadi, S., Afshari, R., Khalaji, S., Rabiee, M., Bagherzadeh, M., Fatahi, Y., Dinarvand, R., Tahriri, M., Tayebi, L., et al. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000076 · Cited by 144
Microglial activation states and their implications for Alzheimer's Disease
Valiukas, Z., Tangalakis, K., Apostolopoulos, V., & Feehan, J. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100013 · Cited by 167
Nano-carrier enabled drug delivery systems for nose to brain targeting for the treatment of neurodegenerative disorders
Md, S., Bhattamisra, S. K., Zeeshan, F., Shahzad, N., Mujtaba, M. A., Meka, V. S., Radhakrishnan, A. K., Kesharwani, P., Baboota, S., & Ali, J. (2017) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2017.09.022 · Cited by 140
New Insights Into Drug Discovery Targeting Tau Protein
Soeda, Y., & Takashima, A. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.590896 · Cited by 136
Autophagy Dysfunction in Alzheimer’s Disease: Mechanistic Insights and New Therapeutic Opportunities
Di Meco, A., Curtis, M. E., Lauretti, E., & Praticò, D. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.05.008 · Cited by 133
Molecular Insight into the Therapeutic Promise of Flavonoids against Alzheimer’s Disease
Uddin, M. S., Kabir, M. T., Niaz, K., Jeandet, P., Clément, C., Mathew, B., Rauf, A., Rengasamy, K. R. R., Sobarzo‐Sánchez, E., Ashraf, G. M., et al. (2020) · Molecules · doi:10.3390/molecules25061267 · Cited by 135
Liquid–liquid phase separation of tau: From molecular biophysics to physiology and disease
Rai, S. K., Savastano, A., Singh, P., Mukhopadhyay, S., & Zweckstetter, M. (2021) · Protein Science · doi:10.1002/pro.4093 · Cited by 129
The proline-rich domain promotes Tau liquid–liquid phase separation in cells
Zhang, X., Vigers, M. P., McCarty, J., Rauch, J. N., Fredrickson, G. H., Wilson, M. Z., Shea, J., Han, S., & Kosik, K. S. (2020) · The Journal of Cell Biology · doi:10.1083/jcb.202006054 · Cited by 122
Potential Bidirectional Relationship Between Periodontitis and Alzheimer’s Disease
Liccardo, D., Marzano, F., Carraturo, F., Guida, M., Femminella, G. D., Bencivenga, L., Agrimi, J., Addonizio, A., Melino, I., Valletta, A., et al. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00683 · Cited by 148
The dendritic hypothesis for Alzheimer's disease pathophysiology
Cochran, J. N., Hall, A. M., & Roberson, E. D. (2014) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2013.12.004 · Cited by 114
A novel DYRK1A (Dual specificity tyrosine phosphorylation‐regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro
Coutadeur, S., Benyamine, H., Delalonde, L., de Oliveira, C., Leblond, B., Foucourt, A., Besson, T., Casagrande, A.-S., Taverne, T., Girard, A., et al. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.13018 · Cited by 121
Microbial involvement in Alzheimer disease development and progression
Bulgart, H. R., Neczypor, E. W., Wold, L. E., & Mackos, A. R. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00378-4 · Cited by 116
Recent Advances in the Treatment of Alzheimer’s Disease Using Nanoparticle-Based Drug Delivery Systems
Poudel, P., & Park, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040835 · Cited by 124
Protein Semisynthesis Provides Access to Tau Disease-Associated Post-translational Modifications (PTMs) and Paves the Way to Deciphering the Tau PTM Code in Health and Diseased States
Haj‐Yahya, M., & Lashuel, H. A. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b02668 · Cited by 118
Therapeutic strategies for the treatment of tauopathies: Hopes and challenges
Khanna, M. R., Kovalevich, J., Lee, V. M. ‐., Trojanowski, J. Q., & Brunden, K. R. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.06.006 · Cited by 116
RETRACTED: The amyloid-β oligomer Aβ*56 induces specific alterations in neuronal signaling that lead to tau phosphorylation and aggregation
Amar, F., Sherman, M. A., Rush, T., Larson, M. E., Boyle, G. E., Liu, C., Götz, J., Buisson, A., & Lesné, S. (2017) · Science Signaling · doi:10.1126/scisignal.aal2021 · Cited by 114
Retracted
Molecular crosstalk between cancer and neurodegenerative diseases
Seo, J., & Park, M. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03428-3 · Cited by 109
Organotypic brain slice cultures to model neurodegenerative proteinopathies
Croft, C. L., Futch, H. S., Moore, B. D., & Golde, T. E. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0346-0 · Cited by 123
Biomarkers in Sporadic and Familial Alzheimer’s Disease
Lista, S., O’Bryant, S. E., Blennow, K., Dubois, B., Hugon, J., Zetterberg, H., & Hampel, H. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-143006 · Cited by 106
Untangling Tau and Iron: Exploring the Interaction Between Iron and Tau in Neurodegeneration
Rao, S. S., & Adlard, P. A. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00276 · Cited by 108
Site‐Specific Hyperphosphorylation Inhibits, Rather than Promotes, Tau Fibrillization, Seeding Capacity, and Its Microtubule Binding
Haj‐Yahya, M., Gopinath, P., Rajasekhar, K., Mirbaha, H., Diamond, M. I., & Lashuel, H. A. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201913001 · Cited by 106
Tau-Based Therapeutics for Alzheimer’s Disease: Active and Passive Immunotherapy
Panza, F., Solfrizzi, V., Seripa, D., Imbimbo, B. P., Lozupone, M., Santamato, A., Tortelli, R., Galizia, I., Prete, C., Daniele, A., et al. (2016) · Immunotherapy · doi:10.2217/imt-2016-0019 · Cited by 113
Mechanistic Link between Vitamin B12 and Alzheimer’s Disease
Lauer, A. A., Grimm, H. S., Apel, B., Golobrodska, N., Kruse, L., Ratanski, E., Schulten, N., Schwarze, L., Slawik, T., Sperlich, S., et al. (2022) · Biomolecules · doi:10.3390/biom12010129 · Cited by 121
Pathological Changes of Tau Related to Alzheimer’s Disease
Chu, D., & Liu, F. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00457 · Cited by 106
Caffeoylquinic Acids in Centella asiatica Protect against Amyloid-β Toxicity
Gray, N. E., Morré, J., Kelley, J., Maier, C. S., Stevens, J. F., Quinn, J. F., & Soumyanath, A. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131913 · Cited by 101
Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region
Agrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Hamano, N., Li, S., Chougule, M. B., Shoyele, S., Gupta, U. D., Ajazuddin, M., et al. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1471058 · Cited by 101
The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer’s disease
Jembrek, M. J., Slade, N., Hof, P. R., & Šimić, G. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.05.001 · Cited by 101
Alzheimer’s disease (AD) therapeutics – 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality
Mullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.026 · Cited by 98
Molecular and functional signatures in a novel Alzheimer’s disease mouse model assessed by quantitative proteomics
Kim, D. K., Park, J., Han, D., Yang, J., Kim, A., Woo, J., Kim, Y., & Mook-Jung, I. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0234-4 · Cited by 95
Dysfunctional Wnt/β-catenin signaling contributes to blood–brain barrier breakdown in Alzheimer’s disease
Liu, L., Wan, W., Xia, S., Kalionis, B., & Li, Y. (2014) · Neurochemistry International · doi:10.1016/j.neuint.2014.05.004 · Cited by 96
Noise exposure accelerates the risk of cognitive impairment and Alzheimer’s disease: Adulthood, gestational, and prenatal mechanistic evidence from animal studies
Jafari, Z., Kolb, B. E., & Mohajerani, M. H. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.04.001 · Cited by 95
miR-106b inhibits tau phosphorylation at Tyr18 by targeting Fyn in a model of Alzheimer's disease
Liu, W., Zhao, J., & Lu, G. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.08.037 · Cited by 92
Protein interaction networks in neurodegenerative diseases: From physiological function to aggregation
Calabrese, G., Molzahn, C. M., & Mayor, T. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102062 · Cited by 92
Small molecule therapeutics for tauopathy in Alzheimer’s disease: Walking on the path of most resistance
Wang, L., Bharti, Kumar, R., Pavlov, P. F., & Winblad, B. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112915 · Cited by 92
Recent developments of protein kinase inhibitors as potential AD therapeutics
Tell, V., & Hilgeroth, A. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00189 · Cited by 92
Resveratrol Suppresses Aβ-Induced Microglial Activation Through the TXNIP/TRX/NLRP3 Signaling Pathway
Feng, L., & Zhang, L. (2019) · DNA and Cell Biology · doi:10.1089/dna.2018.4308 · Cited by 90
Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Reduces Alzheimer Disease-Associated Tau Hyperphosphorylation in the Hippocampus of Rats with Type 2 Diabetes
Xu, W., Yang, Y., Yuan, G., Zhu, W., Ma, D., & Hu, S. (2015) · Journal of Investigative Medicine · doi:10.1097/jim.0000000000000129 · Cited by 90
Mechanistic Link between Vitamin B12 and Alzheimer’s Disease
Lauer, A. A., Grimm, H. S., Apel, B., Golobrodska, N., Kruse, L., Ratanski, E., Schulten, N., Schwarze, L., Slawik, T., Sperlich, S., et al. (2022) · Publications of the UdS (Saarland University) · doi:10.22028/d291-35299 · Cited by 90
Current Pharmacotherapy and Multi-Target Approaches for Alzheimer’s Disease
Cheong, S. L., Tiew, J. K., Fong, Y. H., Leong, H. W., Chan, Y. M., Chan, Z. L., & Kong, E. W. J. (2022) · Pharmaceuticals · doi:10.3390/ph15121560 · Cited by 94
Polygala tenuifolia : a source for anti-Alzheimer’s disease drugs
Deng, X., Zhao, S., Liu, X., Han, L., Wang, R., Hao, H., Jiao, Y., Han, S., & Bai, C. (2020) · Pharmaceutical Biology · doi:10.1080/13880209.2020.1758732 · Cited by 86
Calmodulin Binding Proteins and Alzheimer’s Disease
O’Day, D. H., Eshak, K., & Myre, M. A. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142772 · Cited by 88
The role of heparan sulfates in protein aggregation and their potential impact on neurodegeneration
Maïza, A., Chantepie, S., Vera, C., Fifre, A., Huynh, M. B., Stettler, O., Ouidja, M. O., & Papy-García, D. (2018) · FEBS Letters · doi:10.1002/1873-3468.13082 · Cited by 87
Fyn Kinase Controls Tau Aggregation In Vivo
Briner, A., Götz, J., & Polanco, J. C. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108045 · Cited by 85
Orexin signaling regulates both the hippocampal clock and the circadian oscillation of Alzheimer’s disease-risk genes
Ma, Z., Jiang, W., & Zhang, E. E. (2016) · Scientific Reports · doi:10.1038/srep36035 · Cited by 79
Potential Therapeutic Strategies for Alzheimer’s Disease Targeting or Beyondβ-Amyloid: Insights from Clinical Trials
Jia, Q., Deng, Y., & Qing, H. (2014) · BioMed Research International · doi:10.1155/2014/837157 · Cited by 84
β-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer’s Disease Therapy
Beato, A., Gori, A., Boucherle, B., Peuchmaur, M., & Haudecoeur, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01887 · Cited by 87
Is Huntington's disease a tauopathy?
Gratuze, M., Cisbani, G., Cicchetti, F., & Planel, E. (2016) · Brain · doi:10.1093/brain/aww021 · Cited by 81
An update on the interactions between Alzheimer's disease, autophagy and inflammation
Bostancıklıoğlu, M. (2019) · Gene · doi:10.1016/j.gene.2019.04.040 · Cited by 78
Loss of the m‐AAA protease subunit AFG3L2 causes mitochondrial transport defects and tau hyperphosphorylation
Kondadi, A. K., Wang, S., Montagner, S., Kladt, N., Korwitz, A., Martinelli, P., Herholz, D., Baker, M. J., Schauss, A. C., Langer, T., et al. (2014) · The EMBO Journal · doi:10.1002/embj.201387009 · Cited by 83
Phosphorylation of Human Tau Protein by Microtubule Affinity-Regulating Kinase 2
Schwalbe, M., Biernat, J., Bibow, S., Ozenne, V., Jensen, M. R., Kadavath, H., Blackledge, M., Mandelkow, E., & Zweckstetter, M. (2013) · Biochemistry · doi:10.1021/bi401266n · Cited by 78
Microglia and Wnt Pathways: Prospects for Inflammation in Alzheimer’s Disease
Yang, Y., & Zhang, Z. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00110 · Cited by 76
Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves micro RNA ‐195 down‐regulation
Sun, L., Ban, T., Liu, C., Chen, Q., Wang, X., Yan, M., Hu, X., Su, X., Bao, Y., Sun, L., et al. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13212 · Cited by 76
Micro-RNA-137 Inhibits Tau Hyperphosphorylation in Alzheimer’s Disease and Targets the CACNA1C Gene in Transgenic Mice and Human Neuroblastoma SH-SY5Y Cells
Jiang, Y. Z., Xu, B., Chen, J., Sui, Y., Ren, L., Li, J., Zhang, H., Guo, L., & Sun, X. (2018) · Medical Science Monitor · doi:10.12659/msm.908765 · Cited by 76
Circular RNA Encoded Amyloid Beta peptides—A Novel Putative Player in Alzheimer’s Disease
Mo, D., Li, X., Raabe, C. A., Rozhdestvensky, T. S., Skryabin, B. V., & Brosius, J. (2020) · Cells · doi:10.3390/cells9102196 · Cited by 74
Mammalian target of rapamycin hyperactivity mediates the detrimental effects of a high sucrose diet on Alzheimer's disease pathology
Orr, M. E., Salinas, A., Buffenstein, R., & Oddo, S. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.12.006 · Cited by 78
Formaldehyde, Epigenetics, and Alzheimer’s Disease
Wang, F., Chen, D., Wu, P., Klein, C. B., & Jin, C. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00090 · Cited by 74
Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease
Melchior, B., Mittapalli, G. K., Lai, C., Duong‐Polk, K., Stewart, J., Güner, B., Hofilena, B. J., Tjitro, A., Anderson, S., Herman, D. S., et al. (2019) · Aging Cell · doi:10.1111/acel.13000 · Cited by 73
Intravenous administration of mesenchymal stem cells reduces Tau phosphorylation and inflammation in the 3xTg-AD mouse model of Alzheimer's disease
Neves, A. F., Camargo, C. J., Premer, C., Hare, J. M., Baumel, B. S., & Pinto, M. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113706 · Cited by 77
Melatonin: A potential nighttime guardian against Alzheimer’s
Zhang, Z., Xue, P., Bendlin, B. B., Zetterberg, H., Felice, F. G. D., Tan, X. W., & Benedict, C. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02691-6 · Cited by 76
Exploring the Therapeutic Potential of Phytochemicals in Alzheimer’s Disease: Focus on Polyphenols and Monoterpenes
Piccialli, I., Tedeschi, V., Caputo, L., D’Errico, S., Ciccone, R., De Feo, V., Secondo, A., & Pannaccione, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.876614 · Cited by 73
Morin reverses neuropathological and cognitive impairments in APPswe/PS1dE9 mice by targeting multiple pathogenic mechanisms
Du, Y., Qu, J., Zhang, W., Bai, M., Zhou, Q., Zhang, Z., Li, Z., & Miao, J. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.04.008 · Cited by 72
Structure and Functions of Microtubule Associated Proteins Tau and MAP2c: Similarities and Differences
Melková, K., Zapletal, V., Narasimhan, S., Jansen, S., Hritz, J., Škrabana, R., Zweckstetter, M., Jensen, M. R., Blackledge, M. J., & Žídek, L. (2019) · Biomolecules · doi:10.3390/biom9030105 · Cited by 78
MicroRNA in Alzheimer’s disease revisited: implications for major neuropathological mechanisms
Dehghani, R., Rahmani, F., & Rezaei, N. (2017) · Reviews in the Neurosciences · doi:10.1515/revneuro-2017-0042 · Cited by 72
Protein phosphatase 2A and tau: an orchestrated ‘Pas de Deux’
Taleski, G., & Sontag, E. (2017) · FEBS Letters · doi:10.1002/1873-3468.12907 · Cited by 71
Phosphoregulation of Tau modulates inhibition of kinesin-1 motility
Stern, J. L., Lessard, D. V., Hoeprich, G. J., Morfini, G. A., & Berger, C. L. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e16-10-0728 · Cited by 69
Pathophysiology of Alzheimer’s Disease
Yarns, B. C., Holiday, K. A., Carlson, D. M., Cosgrove, C. K., & Melrose, R. J. (2022) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2022.07.003 · Cited by 68
Role of Post‐translational Modifications in Alzheimer's Disease
Ramesh, M., Gopinath, P., & Govindaraju, T. (2019) · ChemBioChem · doi:10.1002/cbic.201900573 · Cited by 68
New selective glucocorticoid receptor modulators reverse amyloid-β peptide–induced hippocampus toxicity
Pineau, F., Canet, G., Desrumaux, C. M., Hunt, H., Chevallier, N., Ollivier, M., Belanoff, J. K., & Givalois, L. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.05.018 · Cited by 69
Targeting Tau Hyperphosphorylation via Kinase Inhibition: Strategy to Address Alzheimer's Disease
Naqvi, A. A. T., Hasan, G. M., & Hassan, M. I. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200106125910 · Cited by 70

Authors: Martin, L., Latypova, X., Wilson, C. M., Magnaudeix, A., Perrin, M.-L., Yardin, C., & Terro, F.
Affiliations: Inserm (FR)
Centre Hospitalier Universitaire de Limoges (FR)
Université de Limoges (FR)
Corresponding author: Martin, Ludovic
ORCID: Martin, Ludovic
Wilson, Cornelia M.
Magnaudeix, Amandine
Perrin, Marie-Laure
Yardin, Catherine
Terro, Faraj
Venue: Ageing Research Reviews
Publisher: Elsevier BV
Published: 2013-01
Volume: 12
Issue: 1
Pages: 289-309
ISSN: 1568-1637 (ISSN-L)
DOI: 10.1016/j.arr.2012.06.003
OpenAlex: W1988332799
Cited by: 631
References: 326
Citations by year: 2026: 24 · 2025: 62 · 2024: 64 · 2023: 51 · 2022: 79 · 2021: 53 · 2020: 56 · 2019: 46 · 2018: 55 · 2017: 24 · 2016: 34 · 2015: 26 · 2014: 37 · 2013: 17
FWCI: 2.89
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: Ageing Research Reviews (publishedVersion)
PubMed (publishedVersion)
Funders: Université de Nantes
Conseil Régional du Limousin
Institut National de la Santé et de la Recherche Médicale
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Aldose Reductase and Taurine
Keywords: tau phosphorylation, Alzheimer's disease, tau aggregation, kinase inhibition, kinase inhibitors
MeSH terms: Alzheimer Disease, Animals, Humans, Phosphorylation, Protein-Tyrosine Kinases, tau Proteins, Glycogen Synthase Kinase 3, Proline-Directed Protein Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tau protein kinases: Involvement in Alzheimer's disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks